{"id":"NCT03730662","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk","officialTitle":"Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-20","primaryCompletion":"2021-01-22","completion":"2021-04-22","firstPosted":"2018-11-05","resultsPosted":"2022-02-14","lastUpdate":"2022-02-14"},"enrollment":2002,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"5 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"10 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"Insulin Glargine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"10 mg Tirzepatide","deltaMin":-2.43,"sd":0.053},{"arm":"15 mg Tirzepatide","deltaMin":-2.58,"sd":0.053},{"arm":"Insulin Glargine","deltaMin":-1.44,"sd":0.03}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":216,"countries":["United States","Argentina","Australia","Brazil","Canada","Greece","Israel","Mexico","Poland","Puerto Rico","Romania","Russia","Slovakia","Spain","Taiwan"]},"refs":{"pmids":["39531161","37668888","37526908","36152639","35210595","34672967"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/740VpRcJPiyieyyWGYO2ao"]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":329},"commonTop":["Diarrhoea","Nausea","Nasopharyngitis","Decreased appetite","Covid-19"]}}